Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: A feasibility study

British Journal of Cancer

Volumn 75, Issue 5, 1997, Pages 703-709

  Veldhuis, G J ^a   Willemse, P H B ^a   Beijnen, J H ^b   Boonstra, H ^a   Piersma, H ^c   Van Der Graaf, W T A ^a   De Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c MARTINI HOSPITAL   (Netherlands)

Author keywords

Cisplatin; Granulocyte colony stimulating factor; Ifosfamide; Interleukin 3; Ovarian carcinoma; Paclitaxel

Indexed keywords

ALKALINE PHOSPHATASE; ANTIEMETIC AGENT; CISPLATIN; CLEMASTINE; DEXAMETHASONE; GAMMA GLUTAMYLTRANSFERASE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; ONDANSETRON; PACLITAXEL; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 3;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; ESOPHAGITIS; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOPOIESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

EID: 0031054595     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.125     Document Type: Article

References (34)

1. Biesma B, Willemse PHH, Mulder NH. Sleijfer DTh. Gietema JA. Mull R. Limburg PC, Bouma J, Vellenga E and de Vries EGE (1992) Effects of Interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 80: 1141 1148
2. Biesma B. Pokorny R. Kovarik JM. Duffy FA, Willemse PHB, Mulder NH and de Vries EGE (1993) Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer. Cancer Res 53: 5915-5919
3. Bruno E, Briddell R and Hoffmanm R (1988) Effect of recombinant and purified hematopoietic growth factors on human megakaryocyte formation. Exp Hematol 70: 371-377
4. Cersosimo RJ (1989) Cisplatin neurotoxicity. Cancer Treat Rev 16: 195-211
5. D'Hondt V, Weynants P, Humblet Y, Guilaume T, Canon J-L, Beauduin M, Duprez P, Longueville J. Mull R. Chatelain C and Symann M (1993) Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study. J Clin Oncol 11: 2063-2071
6. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD and Goldberg GL (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748-1753
7. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD. Gianni L. Myles J. van der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabárbara P, Onetto M, Winograd B and Canetta R (1994) European-Canadian randomized trial of paclilaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666
8. Gore ME, Preston N, A'Hern RP. Hill C, Mitchell P, Chang J and Nicolson M (1995) Platinum-taxol non-cross resistance in epithelial ovarian cancer. Br J Cancer 71: 1308-1310
9. Huizing MT, Keung ACF, Rosing H. van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM and Beijnen JH (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127-2135
10. Huizing MT, Vermorken JB. Rosing H, ten Bokkel Huinink WW, Mandjes I, Winograd, Pinedo HM and Beijnen JH (1995) Pharmacology of paclitaxel and three main metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3 hour paclitaxel infusion: a European Cancer Center (ECC) trial. Ann Oncol 6: 699-704
11. Jekunen AP, Christen RD, Shalinsky DR and Howell SB (1994) Synergistic interaction between cisplatin and taxol in human ovarian cancer cells in vitro. Br J Cancer 64: 299-236
12. Kelland LR and Abel G (1992) Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-senstive and -resistent human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444-450
13. Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP, Cunnion RE and Reed E (1994) Dose-intense taxol: high response rate in patients with platinum resistant recurrent ovarian cancer. J Natl Cancer Inst 86: 18-24
14. Lu L, Briddell RA, Graham CD, Brandt JE, Bruno E and Hoffman R (1988) Effect of recombinant and purified human haematopoietic growth factors on in vitro colony formation by enriched populations human megakaryocyte progenitor cells. Br J Haematol 70: 149-156
15. Markman M, Hakes Th, Reichman B, Lewis JL, Rubin S, Jones W. Almadrones L, Pizzuto S and Hoskins W (1992) Ifostamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.J Clin Oncol 10: 243-248
16. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Arstrong DK and Donehower RC (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273-279
17. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Arstrong DK and Donehower RC (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273-279
18. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE., Look KY, Clark-Pearson DL and Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
19. Ottmann OG, Abboud M, Welte K, Souza LM and Pelus LM (1989) Stimulation of human hematopoietic progenitor cell proliferation and differentiation by recombinant human interleukin 3. Comparison and interactions with recombinant human granulocyte-macrophage and granulocyte colony-stimulating factors. Exp Hematol 17: 191-197
20. Postmus PE, Gietema JA, Damsma O, Biesma B, Limburg PC, Vellenga E and de Vries HGE (1992) Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose finding study, J Clin Oncol 10: 1131-1140
21. Proost JH and Meijer DKF (1992) MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug moniloring. Comput Biol Med 22: 155-163
22. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere EA, Ettinger DS, Lubejko BG, Clark B. Sartorius SE, Cornblath DR, Hendricks CB and Donehower RC (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692-1703
23. Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE and Reed E (1992) Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10: 1165-1170
24. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C and Spriggs D (1994) Phase I trial of 3 hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer J Clin Oncol 12: 241-248
25. Sevelda P, Mayerhofer K, Obermair A, Stolzlechner J and Kurz C (1994) Thrombosis with paclitaxel. Lancet 343: 727-728
26. Sutton GP, Blessing JA, Homesly HD, Berman ML and Malfetano J (1989) Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 7: 1672-1676
27. Takaue Y, Kawano Y, Reading CL, Watanabe T, Abe T, Ninomiya T, Shimizu E, Ogura T, Kuroda Y, Yokobayashi A, Nakahata T, Asano S and Ventura G (1990) Effects of recombinant human G-CSF, GM-CSF, IL-3 and IL-1α on the growth of purified human peripheral blood progenitors. Blood 76: 330-335
28. Teramura M, Katahira J, Hoshino S, Motoji T, Oshimi K and Mizoguchi H (1998) Clonal growth of human megakaryocyte progenitors in serum-free cultures: effect of recombinant human interleukin 3, Exp Hematol 16: 843-848
29. Theodossiou C, Kroog G, Ettinghausen S, Tolcher A, Cowan K and O'Shaughnessy J (1994) Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5-fluorouracil, doxorubicin. leucovotin, cyclophosphamide, and interleukin-3, Cancer 74: 2808-2810
30. Thigpen JT, Blessing JA., Ball H, Hummel SJ and Barrett RJ (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a gynecologic oncology group study. J Clin Oncol 12: 1748-1753
31. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christina MC, Canetta R, Onetto M, Hayn R and Arbuck SG (1993) Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referal Center 9103. J Clin Oncol 11: 2405-2410
32. Untch M, Sevin B-U, Perras JP, Angioli R, Untch A, Hightower RD. Koechli O and Averette HE (1994) Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol Oncol 53: 44-49
33. Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schröder J and Seeber S (1995) Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A: 92-97
34. Veldhuis GJ, Willemse PHB, van Gameren MM, Aalders JG, Mulder NH, Mull R, Biesma B and de Vries EGE (1995) Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial. J Clin Oncol 13: 733-740